the vault
The Archive
Filter institutional-grade short research by fraud type, research desk and documented outcome. Every dossier links back to the original, full-length report at its source.
Powered by NegativePublicRelations.comSumitomo Chemical & Sumitomo Pharma
The ¥116 Billion Swiss Shuffle: Sumitomo Chemical and Sumitomo Pharma
Gotham City Research alleges Sumitomo Pharma's parent-company financial statements contain an unexplained ¥116 billion irregularity tied to a dividend from its Swiss subsidiary — variously reported as ¥48bn, ¥56bn, and ¥164bn — with the largest figure booked as a non-cash distribution-in-kind of accounts receivable. GCR ties this to a highly anomalous 76% YoY surge in Pharma's receivables (versus 14% revenue growth) and estimates true earnings at both Chemical and Pharma are 50-100% lower than reported, with Chemical's real leverage closer to 6x-10x versus a reported 3.5x. GCR calls both stocks uninvestable and sees 50-100% downside.
Sumitomo Chemical & Sumitomo Pharmaceutical
Sumitomo Chemical & Sumitomo Pharmaceutical: The 116 Billion Swiss Shuffle
Gotham City Research published Part I of its investigation into Sumitomo Chemical (4005) and Sumitomo Pharmaceutical (4506), titled 'The 116 Billion Swiss Shuffle.' The report alleges that Sumi Pharma's FY2025 financial statements are misstated by 116-165 billion JPY and will be restated, with an investigation to follow. Sumitomo Pharma FY2025 earnings account for 92% of Sumitomo Chemical FY2025 earnings, and both companies' earnings are inflated by non-recurring sources. Pharma's receivables grew 76% YoY while revenue grew only 14%, suggesting channel stuffing, aggressive revenue recognition, or fictitious revenue. The centerpiece of the report is a discrepancy between a 48 billion JPY dividend announced from Switzerland subsidiary SMPS to Pharma (weeks before a 116.4 billion JPY public offering) and the 164 billion JPY dividend actually paid per the parent company's financial statements — an unexplained 116 billion JPY gap. The 164 billion dividend was a distribution in-kind (accounts receivables), does not appear on the income statement, and implies the parent company is loss making. Without the manipulated receivables, Chemical's leverage is ~10x rather than the reported ~3x. Gotham City concludes shares of both Chemical and Pharma are uninvestable and face 50%-100% downside risk.
China Gold International Resources Corp
China Gold International Resources Corp — Critical Analysis: 50-75% Downside Risk from Governance Failures and CNG Dependency
Spruce Point Capital is short China Gold International Resources Corp Ltd. (TSX: CGG / HK: 2099), a Vancouver-based company with two mines in the Tibet and Inner Mongolia autonomous regions of China. The forensic review raises serious concerns about management, Board governance, related party dealings with largest shareholder China National Gold (CNG) — which represented 99.5% of total revenue in 2025 — a web of auditors and financial/geologic advisors, and ESTMA reporting delinquency. Two former CEOs/Chairmen have been reprimanded (one serving prison time), and the new independent financial advisor is linked to Ms. Ma Xiaoqiu, reportedly charged with fraud and money laundering in Shenzhen. Spruce Point estimates 50-75% downside risk to CGG's share price.
The Ensign Group
ENSG Rents Administrator Licenses at ~20% of Facilities — ~$7B False Claims Act Exposure
Muddy Waters concludes that ENSG engages in a systematic scheme at an estimated ~20 of its 379 Skilled Nursing Facilities to rent the licenses of Administrators who are not generally present at, nor actually managing, the facilities. This scheme — which could amount to fraud against states, Medicare, and Medicaid — is the pillar upon which ENSG's acquisition strategy and margins are built. Federal law requires each SNF have a licensed Administrator to be eligible to bill Medicare and Medicaid (69% of revenue). Under the False Claims Act, violations could lead to theoretical sanctions of ~$7 billion. Compliance alone would reduce 2027 EBIT by ~35% vs consensus.
Sigma Lithium Corporation
Blue Orca Capital Is Short Sigma Lithium: Undisclosed Brazilian Lawsuits, a Bombshell Safety Report, and a Liquidity Crisis
Blue Orca Capital disclosed a short position in Sigma Lithium (SGML), alleging the company failed to disclose a technical report claiming its Grota do Cirilo mine has pit walls so steep they create a 'high potential for loss of human life,' along with a sealed $22 million lawsuit from its former mining contractor, over a dozen additional creditor actions, a $2 million U.S. arbitration judgment, an emergency Brazilian state prosecutor lawsuit seeking to freeze $9.2 million of its cash, and federal prosecutor demands to annul its mining and environmental licenses.
Zoom Communications, Inc.
Zoom Communications — Zooming to Share Price Upside: 83% Upside from Capital Allocation and Expense Reforms
Spruce Point Capital is LONG Zoom Communications, Inc. (Nasdaq: ZM) — a rare strong-buy recommendation. After a forensic review, Spruce Point sees material upside potential, viewing Zoom as a market leader trading well below intrinsic value, including an estimated $1.2B stake in AI leader Anthropic. The report outlines nine core recommendations to accelerate shareholder value creation: improve capital allocation ($4B Dutch auction tender + $1/share dividend), reduce operating expenses, restructure the underperforming international business, improve marketing, avoid M&A mistakes, and consolidate insider selling. Spruce Point estimates 83% share upside from EBITDA multiple re-rating (9.5x to 19x) and $172M of incremental EBITDA.
Sportradar Group AG
Sportradar Aids and Abets Illegal Gambling — 20-40% of Revenue from Illegal Operators
Muddy Waters is short Sportradar Group AG (SRAD). At the ICE 2026 gaming conference in Barcelona, undercover investigators posing as a startup sportsbook targeting banned markets (Vietnam, Thailand, Indonesia, China) were not turned away by any SRAD salesperson. An Asia-focused executive offered to introduce them to the Yabo Group — China's largest illegal gambling operator, staffed by trafficked workers. Muddy Waters estimates illegal operators deliver 20-40% of SRAD's total revenues, and identified nearly 50 companies operating in illegal markets as current or recent SRAD clients, including 1xBet, FonBet, 8xBet, OKVIP, SBOBet, and Yabo Group. SRAD's CEO Carsten Koerl's claims of a '4-level' KYC process and close monitoring of illegal activity are contradicted by the undercover investigation, SRAD's own website code, and testimony of 15 current and former employees.
SoFi Technologies
SOFI Booked a $312M Loan as a Sale — Inflating Profits and Executive Bonuses While Shareholders Bear ~15% Annual Dilution
Muddy Waters is short SOFI. SOFI's management appears to have booked a $312 million loan from JPMorgan as if it were a sale — inflating reported profits and their own bonuses while shareholders bear ~15% annual dilution. Utah UCC filings contradict SOFI's accounting, suggesting SOFI needs to restate this transaction. The restatement should be much larger than just $312 million: when SOFI restates this borrowing, it will also restate ~$1 billion of previously reported EBITDA, and its capital ratios will be restated materially lower.
Bunge Global SA
Bunge Global SA — Slimming Down A Fat Share Price: 55-80% Downside from Debt-Financed Returns and Core Decline
Spruce Point Capital is short Bunge Global SA (NYSE: BG), an S&P 500 global agribusiness, and calls for an independent investigation into the accuracy of its financial reporting and accounting. Spruce Point views Bunge as a complex and troubled roll-up that has demonstrated an inability to deliver value to shareholders absent external financing — since 1999, it has generated a cash flow deficit of -$1.6bn after capex while making +$4.7bn in dividends and +$3.9bn in buybacks effectively through debt-financing. The $10.6bn Viterra acquisition from Glencore is viewed as a deal borne out of necessity to deflect from core oilseeds challenges, and has wildly disappointed. Spruce Point estimates 55-80% downside risk and warns of extreme insider selling of up to 30% of the stock.
SoFi Technologies
SOFI's 2025 Adjusted EBITDA Is Inflated by ~90% — 11 Questions SOFI Refuses to Answer
Muddy Waters is short SOFI. On March 17, the firm published a 28-page report concluding that SOFI's 2025 Adjusted EBITDA is inflated by approximately 90%. SOFI's response was a press release that did not address a single factual claim. CEO Noto purchased $500,000 of stock — roughly 0.86% of the $58.3 million he and CFO Lapointe have already extracted through prepaid variable forward contracts. Five days later, SOFI has still not engaged with any specific allegation in the report.
Nova Minerals Limited
Nova Minerals Limited — Critical Evaluation: 45-60% Downside (up to 100%) from Unverifiable Expert and Infrastructure Gaps
Spruce Point Capital is short Nova Minerals Ltd. (Nasdaq / ASX: NVA), a company with ambitions of becoming an integrated producer of antimony and a Tier 1 gold miner. Spruce Point believes investor expectations are too high given significant commercial challenges (lack of infrastructure, community pushback, harsh Alaskan weather, lack of proof of concept). Concerns include management/Board/shareholder links to individuals charged with market manipulation by ASIC and SEC, an unverifiable consulting geologist responsible for data evaluation and quality control, frequent strategic pivots, and missed project timetables. Spruce Point estimates 45-60% downside ($2.50-$3.50/ADS), but up to 100% downside if the $43.5m Department of War award is lost.
Carvana Co.
Carvana: New Information Reveals that Bridgecrest Is the Lienholder — CVNA Must Explain How and How Much
In a follow-up report, Gotham City Research says it has on-the-record evidence — Carvana's own Better Business Bureau responses — of Carvana identifying Bridgecrest (DriveTime's financing arm) as the lienholder on cars Carvana sold, contradicting Carvana's own website, which names Carvana as lienholder and Bridgecrest as merely a 'third-party loan servicer.' GCR identifies 34 additional VINs it says end up with Bridgecrest as lienholder, and says vehicle-history records show Bridgecrest, not Carvana, is now the current lienholder on the original 34 VINs from its first report, undercutting a JPMorgan rebuttal. GCR argues this matters because Carvana's Gain on Loan Sales -- effectively all of its reported earnings -- appears ultimately tied to the heavily leveraged, related-party DriveTime/Bridgecrest, a dependency GCR says Carvana has not adequately explained.
Carvana
Carvana: New Information Reveals that Bridgecrest is the Lienholder — CVNA Must Explain How and How
Gotham City Research published a follow-up report on Carvana (CVNA) revealing new information that Bridgecrest, not Carvana, is the lienholder on cars Carvana sold. The report presents on-the-record evidence of Carvana stating that Bridgecrest is the lienholder, identifies 34 new vehicles/VINs where Bridgecrest is the ultimate lienholder, and shows via detailed lienholder history records that Bridgecrest is the most recent lienholder of the original 34 VINs from the prior report. Gotham City explains that Carvana sells cars without title and issues temporary out-of-state plates while awaiting registration, causing chronic mismatches between ABS Obligor State fields and title record states. The report also alleges that Carvana's Gain on Loan Sales are ultimately tied to DriveTime/Bridgecrest, despite Carvana narrowly claiming it hasn't sold loans directly to DriveTime in years, and calls on CVNA management to explain the mechanism by which its loans end up at DriveTime/Bridgecrest.
Super Group (SGHC) Limited
Super Group (SGHC) — A Super Simple Short Thesis: 20-50% Downside from Material EBITDA Overstatement
Spruce Point Capital is short Super Group (SGHC) Ltd (NYSE: SGHC), an online sports betting and gaming company and 2022 vintage SPAC transaction domiciled in Guernsey. Spruce Point identified a material omission of a minority ownership interest in its crown-jewel South African subsidiary, Raging River Trading (Pty) Ltd. SGHC's 20-F claims 100% ownership, but a May 2024 public notice from the Western Cape Gambling and Racing Board and a November 2024 B-BBEE verification certificate confirm a 10.71% minority interest (Betway Cares Foundation NPC), reducing SGHC's ownership to 89.29%. If improperly consolidating 100% rather than 89.29%, SGHC may be overstating 2025E EBITDA by approximately $30.7 million. Spruce Point estimates 20-50% downside to $4.25-$6.80 per share.
Resideo Technologies, Inc.
Resideo Technologies — Red Alert: Where There's Smoke, There's Fire: 25-50% Downside from Value-Destructive M&A and Accounting Strains
Spruce Point Capital is short Resideo Technologies, Inc. (NYSE: REZI) and calls for an independent investigation into the accuracy of its financial reporting and accounting. As a troubled spin-off from Honeywell in 2018, Resideo has failed to achieve its long-term financial goals, suffers from years of organizational complexity, and has failed to fix lingering technology issues. Spruce Point provides analysis suggesting Resideo has engaged in value-destructive M&A with questionable financial reporting to bolster the appearance of earnings growth, with the First Alert (2022) and Snap One Holdings (2024) acquisitions being particularly troubled. The announced split-up is viewed as a red herring to distract from weakening competitive positioning, diminished growth vectors, and growing accounting strains. Resideo is now precariously levered at 5.5x (up from 3.3x in 2018). Spruce Point sees 25-50% downside to approximately $17.64-$26.45 per share.
IperionX Ltd.
IperionX Ltd. — Critical Analysis: 70-95% Downside from HAMR Technology Doubts, No Revenue, and CEO Conflicts
Spruce Point Capital is short IperionX Ltd. (Nasdaq / ASX: IPX), a company with ambitions of becoming a vertically integrated producer of titanium powders and products. Spruce Point believes investor expectations are too high and expresses concerns with the accuracy of its financial reporting. Key concerns include significant management overlap with the collapsed Piedmont Lithium, doubts about the HAMR technology's ability to displace the 70-year-old Kroll process, oversupplied end markets, no revenue despite a Ford contract, Titan project delays, financial reporting discrepancies, and evidence of potential breach of duty by CEO Taso Arima related to undisclosed entities (PowerChem, GX Technologies). IPX trades at 9.7x and 24x book value and 2026E revenues vs. industry medians of 1.4x and 1.8x. Spruce Point estimates 70-95% downside risk.
DraftKings Inc.
DraftKings Inc. — Predicting More Downside Risk: 35-60% Downside from Prediction Market Disruption
Spruce Point Capital is short DraftKings Inc. (Nasdaq: DKNG) on the thesis that emerging prediction markets like Kalshi and Polymarket will take more sportsbook market share than investors and sell-side analysts predict. Spruce Point believes prediction exchanges will continue to operate while state litigation drags on, with the U.S. Supreme Court unlikely to decide on legality until summer 2027. DKNG is forced to sit on the sidelines as state gaming commissions have warned sportsbooks not to enter prediction markets. Kalshi appears to offer better odds than DKNG, driving rapid handle growth. The market has misinterpreted Kalshi's handle and hold rate, and sell-side analysts have been reluctant to lower consensus revenue estimates. Spruce Point estimates 35-60% downside risk.
Sumitomo Pharmaceutical
Sumitomo Chemical & Sumitomo Pharmaceutical Part II: CiRA, Dr. Yamanaka, and the Undisclosed History of Research Fraud
Gotham City Research published Part II of its investigation into Sumitomo Chemical and Sumitomo Pharmaceutical, focusing on the Center for iPS Cell Research & Application (CiRA) and its founder Dr. Shinya Yamanaka. Sumitomo Pharma targets 350 billion JPY in iPS cell revenue, including from Amchepry, and CiRA is its research partner, iPS cells supplier, and trial conductor. Gotham City Research identified two well-documented cases of fraud involving CiRA and Yamanaka (2014 and 2018), plus 8 additional problematic cases — including one research paper where the Amchepry trial's lead investigator is an author. Amchepry depends entirely on CiRA's integrity, which Gotham City considers suspect and unreliable. Notably, Takeda recently terminated its 10-year partnership with CiRA while Sumitomo goes all-in. Gotham City's opinion is that Sumi Pharma's FY2025 financial statements are misstated by 116-165 billion JPY and will be restated, with an investigation to follow.
Adler Group
Bond-fuelled property valuations and undisclosed related-party dealing
Viceroy argued Adler's German property portfolio was systematically overvalued and that a web of undisclosed related-party transactions moved assets at prices designed to support the balance sheet rather than reflect the market.
Dun & Bradstreet
Aggressive accounting and unsustainable growth claims post-relisting
Spruce Point argued that Dun & Bradstreet's post-IPO organic growth relied on aggressive revenue recognition, capitalisation choices and acquisition accounting that flattered adjusted earnings well beyond underlying performance.
XL Fleet
Overstated backlog and misleading customer claims at a SPAC-listed electrification story
Muddy Waters alleged XL Fleet inflated its sales pipeline and misrepresented customer relationships and product performance following its SPAC merger, based on interviews with former employees and customers.
Ebix Inc.
Audit resignations, gift-card revenue and an unravelling India business
Research focused on Ebix's Indian gift-card business, where auditors were unable to obtain sufficient evidence over trade receivables. The auditor resigned; the company later filed for Chapter 11.
Nikola Corporation
An ocean of lies: product claims with no underlying technology
Short-side research argued Nikola's hydrogen truck claims were unsupported by working technology, most infamously a promotional video of a truck rolling downhill rather than driving under its own power. The founder resigned days later and was later convicted of fraud.
Wirecard AG
The great fintech illusion: third-party acquiring and missing trust cash
Research on Wirecard's third-party acquiring business argued that the bulk of reported profit sat in opaque Asian partners whose cash could not be verified. €1.9 billion of trust account cash was subsequently found not to exist.
Luckin Coffee
Fabricated store-level sales and inflated per-store transaction volume
An anonymous 89-page report plus thousands of hours of store video alleged that Luckin fabricated store-level per-day items sold and inflated advertising expense to funnel cash out. The company later admitted roughly RMB 2.2 billion of fabricated sales.
China Feihe
Overstated infant formula revenues and understated marketing costs
Blue Orca argued China Feihe overstated revenue and profitability relative to channel evidence and understated advertising and distribution expense. The company rejected the findings and the shares later recovered — a reminder that not every case resolves the short seller's way.
Axos Financial
Opaque lending book and questionable governance at a high-growth digital bank
Spruce Point questioned the credit quality of Axos's specialty lending book, the adequacy of loss provisioning, and governance and disclosure practices at a bank whose growth outpaced comparable digital lenders.
Samsonite International
Inflated margins via undisclosed related-party acquisitions and a fabricated CEO credential
Blue Orca alleged Samsonite inflated profits through the accounting treatment of an undisclosed related-party acquisition and highlighted that the CEO had misrepresented his doctoral credential. Trading was suspended and the CEO resigned within days.
Valeant Pharmaceuticals
The pharmaceutical Enron: phantom accounts and channel stuffing via Philidor
Citron alleged Valeant used a captive specialty pharmacy network, principally Philidor, to create phantom sales and inflate reported revenue — likening the structure to Enron's off-balance-sheet entities.
Sino-Forest Corporation
A multibillion-dollar Ponzi scheme with fraudulent timber assets
The report alleged Sino-Forest overstated timber holdings and revenue through opaque "authorised intermediaries" that left no verifiable paper trail. Trading was halted, the CEO resigned, and the company filed for creditor protection.